New nanoparticle therapy tested for autoimmune liver disease – first human trial complete

This first-in-human study tested a single dose of PVT201, a nanoparticle-based drug, in 24 people: healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The main goal was to check safety and how the drug moves through the body. All patients received the drug, while some healthy volunteers got a placebo. This early research does not yet test whether the drug works, but it is a necessary step toward developing a new treatment for these autoimmune liver diseases.